Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Gilles Montalescot,
a. aspirin+clopisogrel+VKA 67%b. aspirin+prasugrel or ticagrelor+VKA 8%c. aspirin+clopidogrel+NOAC (dabigatran or rivaroxaban) 18%d. aspirin+prasugrel or ticagrelor+NOAC 7%
a. 3 Months 30%b. 6 Months 37%c. 12 Months 33%
The answers to this poll make sense and the 85% of cardiologists ticking a or c are certainly correct. -The association of a new P2Y12 antagonist with a vitamin K antagonist has not been properly tested and there is an official warning in the label of these drugs (prasugrel and ticagrelor) to avoid this association; the patients run the risk of serious bleeding and if such double or triple therapy is used the reasons for the prescription should be documented in the medical records and specific information provided to the patient. -a similar comment can be made for the association of prasugrel or ticagrelor with a NOAC. Although there may be a rationale in particular in terms of safety, we clearly need more data before recommending such a strategy.-aspirin+ clopidogrel + NOAC is a possibility, certainly safer than a vitamin K antagonist with aspirin and clopidogrel. Renal function needs to be checked first for eventual adjustment of the doses of these NOACs.-one option has not been proposed which is to keep only one antiplatelet agent (clopidogrel) as tested in the WOEST trial, in combination with a vitamin K antagonist. Because this is only one trial, we need confirmation from other trials to confirm that this strategy is a valid option.-However the results from WOEST and the recent information obtained with the last generation of DES showing a negligible stent thrombosis rate beyond 3 months, suggest that 3 months of triple therapy may be enough. If the patient is at high risk of recurrent coronary event, 6 months may be preferred. Again the cardiologists polled were correct in their votes in this second question of the Poll.
European Society of Cardiology
European Heart HouseLes Templiers2035 Route des CollesCS 80179 BIOT
06903Sophia Antipolis, FR
© 2017 European Society of Cardiology. All rights reserved